Table 2 Comparison of patients characteristics according to the sickle cell haplotypes
Homozygous Bantu | Heterozygous Bantu | Homozygous Benin | Heterozygous Benin | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bantu/Bantu (n = 95) | P | Bantu/− (n = 46) | P | Benin/Benin (n = 4) | P | Benin/− (n = 35) | p | |||||
Mean (±SD) or n (%) | Mean (±SD) or n (%) | Mean (±SD) or n (%) | Mean (±SD) or n (%) | |||||||||
Age (years) | 7,98 (±0,82) | 11,23 (±0,55) | 0,002 | |||||||||
Hématocrit (%) | 24,18 (±0,38) | 26,26(±0,51) | 0,001 | 26,26 (±0,6) | 24,43 (±0,36) | 0,01 | ||||||
MCV (fL) | 81,27 (±1) | 67,78 (±1,23) | < 0,001 | 66,72 (±1,42) | 80,04 (±0,97) | < 0,001 | ||||||
MCHC (g/dL) | 32,75 (±0,13) | 31,43 (±0,24) | < 0,001 | 32,22 (±0,13) | 33,72 (±0,74) | 0,023 | 34,25 (±1,04) | 32,23 (±0,13) | 0,011 | |||
HbF (%) | 13,11 (±0,7) | 6,08 (±2,3) | 0,044 | 4,01 (±2,7) | 13,07 (±0,7) | 0,034 | 12 (±0,75) | 15,1 (±1,52) | 0,048 | |||
HbS (%) | 85,9 (±1,1) | 79,67 (±1,36) | 0,001 | 78,68 (±1,62) | 85,48 (±0,98) | 0,001 | ||||||
TCD | 0,041 | |||||||||||
Normal | 1 (33,3) | 101 (83,4) | ||||||||||
Limit | 0 | 10 (8,3) | ||||||||||
Pathological | 2 (66,7) | 10 (8,3) | ||||||||||
Duration of follow-up (months) | 87,57 (±5,03) | 143,7 (±30,43) | 0,032 | 153 (±37,4) | 87,7 (±5) | 0,025 | ||||||
Newborn screening | 29 (74,3) | 8 (7,3) | 0,001 | |||||||||
Treatment Iron chelator | 2 (50%) | 9 (6,3) | 0,028 | |||||||||
Hospitalization/year | 0,012 | 0,002 | ||||||||||
No | 9 (9,6) | 13 (25,5) | 12 (30,7) | 10 (9,5) | ||||||||
1 à 2 | 75 (79,8) | 37 (72,5) | 27 (69,3) | 85 (80) | ||||||||
≥3 | 10 (10,6) | 1 (2) | 0 | 11 (10,5) | ||||||||
RBC transfusion | 0,046 | |||||||||||
Never | 18 (18,9) | 19 (37,3) | ||||||||||
Occasionnally | 63 (66,4) | 28 (54,9) | ||||||||||
chronic transfusion | 14 (14,7) | 4 (7,8) | ||||||||||